Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Eligo Bioscience is a clinical-stage biotechnology company pioneering the development of novel, CRISPR-based drugs called Eligobiotics® to selectively target and modify the microbiome. Their innovative approach aims to address a wide range of diseases by precisely editing the genetic makeup of bacteria within the gut and other microbial ecosystems, offering potential treatments for conditions from infectious diseases to inflammatory disorders and beyond. Eligo's technology allows for the selective eradication of pathogenic bacteria or the delivery of therapeutic genes to beneficial bacteria, marking a significant advancement in precision medicine.
Primary research and development (R&D) labs, corporate operations, strategic partnerships, and administrative functions.
State-of-the-art laboratory facilities equipped for advanced microbiology, molecular biology, and gene editing research, including BSL-2 capabilities. Part of the Biocitech campus, fostering collaboration and innovation.
A dynamic, science-driven, and innovative environment focused on cutting-edge research. Emphasizes collaboration, intellectual curiosity, and a mission to translate scientific breakthroughs into impactful therapies.
The headquarters serves as the central nervous system for Eligo's pioneering work in microbiome gene therapy, strategically positioned within a leading European biotech ecosystem to leverage talent and partnerships.
Eligo Bioscience's core operations and R&D are centered in Paris, France. They maintain a global outlook through international collaborations, participation in global scientific conferences, and a strategic presence in key biotech hubs like Cambridge, MA, USA, to support business development, clinical trial activities, and investor relations worldwide as their therapeutic pipeline advances.
102 Av. Gaston Roussel
Romainville (Greater Paris)
Île-de-France
France
Address: Not publicly specified; likely a strategic presence or collaborative office rather than a full R&D site.
To engage with the North American biotech ecosystem, facilitate partnerships, and access US capital markets and clinical research expertise.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Eligo Bioscience' leadership includes:
Eligo Bioscience has been backed by several prominent investors over the years, including:
Eligo Bioscience has strengthened its leadership, notably with the appointment of a new Chief Medical Officer in late 2023. The company continues to build its team to support clinical development.
Discover the tools Eligo Bioscience uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Eligo Bioscience commonly uses the email format combining the first initial and last name, or first name and last name separated by a dot, followed by @eligo.bio. This is a standard convention for many biotechnology companies.
[first_initial][last]@eligo.bio or [first].[last]@eligo.bio
Format
jdoe@eligo.bio or jane.doe@eligo.bio
Example
85%
Success rate
Eligo Bioscience Press Release • November 29, 2023
Eligo Bioscience announced the appointment of Dr. Sophie Lipsett as Chief Medical Officer. Dr. Lipsett will oversee the clinical development strategy and operations for Eligo's pipeline of innovative microbiome gene therapies....more
Eligo Bioscience Press Release • September 7, 2023
Eligo Bioscience announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EB005, its investigational therapy for the treatment of recurrent Clostridioides difficile Infection (rCDI). EB005 is designed to selectively eliminate C. difficile bacteria from the gut microbiome....more
Eligo Bioscience Press Release • June 12, 2023
Eligo Bioscience presented promising preclinical data for EB005 at the American Society for Microbiology (ASM) Microbe 2023 conference. The data showcased EB005's ability to potently and selectively kill Clostridioides difficile bacteria while preserving beneficial commensal bacteria in complex human gut microbiome models....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Eligo Bioscience, are just a search away.